Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease [PDF]
Clinical and Translational Science, 2021 Apomorphine is an on‐demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD). A joint parent‐metabolite population pharmacokinetic (PK) model characterized apomorphine and apomorphine‐sulfate following administration of apomorphine ...
Felix Agbo +6 more
doaj +2 more sources
Identification of the efficacy and safety of apomorphine in the treatment of Parkinson’s disease via meta-analysis [PDF]
BMC NeurologyBackground The majority of Parkinson’s disease (PD) patients experience motor fluctuations and dyskinesias as the disease progresses. Apomorphine has been used as an acute treatment for off episodes in PD in recent years.
Haidong Li +3 more
doaj +2 more sources
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson’s Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis [PDF]
Neurology and TherapyIntroduction Parkinson’s disease is the second most common neurodegenerative disorder. In advanced Parkinson’s disease, subcutaneous (SC) infusion therapies represent minimally invasive and reversible treatment options.
Marc Vérin +9 more
doaj +2 more sources
Ophthalmic ropinirole is an equally effective emetic agent in healthy dogs compared to intravenous apomorphine [PDF]
Frontiers in Veterinary ScienceIntroductionEmesis is commonly induced in the veterinary setting due to toxin or foreign material ingestion. The dopamine agonist apomorphine is commonly used for this indication.
Jack A. Lee +3 more
doaj +2 more sources
Clinical Parkinsonism & Related Disorders, 2023 Introduction: Pretreatment with the antiemetic trimethobenzamide has been recommended practice in the United States (US) to address the risk of nausea and vomiting during initiation of apomorphine treatment.
Stuart H. Isaacson +3 more
doaj +1 more source
Subcutaneous apomorphine in advanced Parkinson’s disease and its use in Indian population
Annals of Movement Disorders, 2020 Although subcutaneously administered apomorphine is widely used as an effective adjunct therapy for Parkinson’s disease (PD), it was approved for use in India only in 2019. This review summarizes the history, pharmacology, clinical spectrum, indications,
Vinod Metta +7 more
doaj +1 more source
Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish
Frontiers in Neuroscience, 2022 Ankyrin repeat and kinase domain containing 1 (ANKK1) is a member of the receptor-interacting protein serine/threonine kinase family, known to be involved in cell proliferation, differentiation and activation of transcription factors.
Adele Leggieri +9 more
doaj +1 more source
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Asian Journal of Pharmaceutical Sciences, 2018 Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss.
Nrupa Borkar, Huiling Mu, René Holm
doaj +1 more source
Pakistan Journal of Pharmaceutical Sciences, 2020 Drug abuse and impaired adaptation to stress are inter-related. Drug abuse is more potentiated upon exposure to stress and an impairment to cope with stress may lead to depression.
Huma Ikram +4 more
doaj +1 more source
Arquivos de Neuro-Psiquiatria, 2021 Background: Impulsive compulsive behaviors (ICBs) can affect a significant number of Parkinson’s disease (PD) patients. Objective: We have studied brain samples from a brain bank of PD patients who received apomorphine via continuous infusion in life to
Pedro Barbosa +3 more
doaj +1 more source